SymBio Financial Statements From 2010 to 2026
| SYMQY Stock | USD 0.64 0.00 0.00% |
Check SymBio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SymBio Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . SymBio financial statements analysis is a perfect complement when working with SymBio Pharmaceuticals Valuation or Volatility modules.
SymBio |
SymBio Pharmaceuticals Limited Company Return On Equity Analysis
SymBio Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SymBio Pharmaceuticals Return On Equity | 0.15 |
Most of SymBio Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SymBio Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, SymBio Pharmaceuticals Limited has a Return On Equity of 0.1546. This is 100.64% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 149.87% lower than that of the firm.
SymBio Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SymBio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare SymBio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SymBio Pharmaceuticals competition to find correlations between indicators driving SymBio Pharmaceuticals's intrinsic value. More Info.SymBio Pharmaceuticals Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.84 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SymBio Pharmaceuticals Limited is roughly 1.19 . Comparative valuation analysis is a catch-all model that can be used if you cannot value SymBio Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for SymBio Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About SymBio Pharmaceuticals Financial Statements
SymBio Pharmaceuticals investors use historical fundamental indicators, such as SymBio Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SymBio Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan. Symbio Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 141 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for SymBio Pink Sheet Analysis
When running SymBio Pharmaceuticals' price analysis, check to measure SymBio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SymBio Pharmaceuticals is operating at the current time. Most of SymBio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of SymBio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SymBio Pharmaceuticals' price. Additionally, you may evaluate how the addition of SymBio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.